Workflow from Scientific Research

The concomitant regimen involved patients receiving a combination of RO6870810 and atezolizumab from initiation. Tumor biopsies for RNA-sequencing and immunohistochemistry (IHC) were taken at baseline (Cycle 1 Day 1 [C1 D1]) and post-first cycle (Cycle 1 Day 21 [C1 D21]), indicated by purple arrows. Peripheral blood samples for flow cytometry and cytokine profiling, shown by red arrows, were collected on days 1, 8, 15, and 21. This regimen was applied to patients in the dose escalation and both expansion cohorts.

DOI